Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria

Sally Arai, Madan Jagasia, Barry Storer, Xiaoyu Chai, Joseph Pidala, Corey Cutler, Mukta Arora, Daniel J. Weisdorf, Mary E.D. Flowers, Paul J. Martin, Jeanne Palmer, David Jacobsohn, Steven Z. Pavletic, Georgia B. Vogelsang, Stephanie J. Lee

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

In 2005, the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD proposed a new scoring system for individual organs and an algorithm for calculating global severity (mild, moderate, severe). The Chronic GVHD Consortium was established to test these new criteria. This report includes the first 298 adult patients enrolled at 5 centers of the Consortium. Patients were assessed every 3-6 months using standardized forms recommended by the Consensus Conference. At the time of study enrollment, global chronic GVHD severity was mild in 10% (n ∇ 32), moderate in 59% (n ∇ 175), and severe in 31% (n ∇ 91). Skin, lung, or eye scores determined the global severity score in the majority of cases, with the other 5 organs determining 16% of the global severity scores. Conventional risk factors predictive for onset of chronic GVHD and nonrelapse mortality in people with chronic GVHD were not associated with NIH global severity scores. Global severity scores at enrollment were associated with nonrelapsemortality (P < .0001) and survival (P < .0001); 2-year overall survival was 62% (severe), 86% (moderate), and 97% (mild). Patients with mild chronic GVHD have a good prognosis, while patients with severe chronic GVHD have a poor prognosis. This study was registered at www.clinicaltrials.gov as no. NCT00637689.

Original languageEnglish (US)
Pages (from-to)4242-4249
Number of pages8
JournalBlood
Volume118
Issue number15
DOIs
StatePublished - Oct 13 2011
Externally publishedYes

Fingerprint

Graft vs Host Disease
Grafts
Consensus
Skin
Health
Time and Motion Studies
Survival
National Institutes of Health (U.S.)
Clinical Trials
Lung
Mortality

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Arai, S., Jagasia, M., Storer, B., Chai, X., Pidala, J., Cutler, C., ... Lee, S. J. (2011). Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria. Blood, 118(15), 4242-4249. https://doi.org/10.1182/blood-2011-03-344390

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria. / Arai, Sally; Jagasia, Madan; Storer, Barry; Chai, Xiaoyu; Pidala, Joseph; Cutler, Corey; Arora, Mukta; Weisdorf, Daniel J.; Flowers, Mary E.D.; Martin, Paul J.; Palmer, Jeanne; Jacobsohn, David; Pavletic, Steven Z.; Vogelsang, Georgia B.; Lee, Stephanie J.

In: Blood, Vol. 118, No. 15, 13.10.2011, p. 4242-4249.

Research output: Contribution to journalArticle

Arai, S, Jagasia, M, Storer, B, Chai, X, Pidala, J, Cutler, C, Arora, M, Weisdorf, DJ, Flowers, MED, Martin, PJ, Palmer, J, Jacobsohn, D, Pavletic, SZ, Vogelsang, GB & Lee, SJ 2011, 'Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria', Blood, vol. 118, no. 15, pp. 4242-4249. https://doi.org/10.1182/blood-2011-03-344390
Arai, Sally ; Jagasia, Madan ; Storer, Barry ; Chai, Xiaoyu ; Pidala, Joseph ; Cutler, Corey ; Arora, Mukta ; Weisdorf, Daniel J. ; Flowers, Mary E.D. ; Martin, Paul J. ; Palmer, Jeanne ; Jacobsohn, David ; Pavletic, Steven Z. ; Vogelsang, Georgia B. ; Lee, Stephanie J. / Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria. In: Blood. 2011 ; Vol. 118, No. 15. pp. 4242-4249.
@article{077b03c26fa64112816a5296cd4263d8,
title = "Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria",
abstract = "In 2005, the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD proposed a new scoring system for individual organs and an algorithm for calculating global severity (mild, moderate, severe). The Chronic GVHD Consortium was established to test these new criteria. This report includes the first 298 adult patients enrolled at 5 centers of the Consortium. Patients were assessed every 3-6 months using standardized forms recommended by the Consensus Conference. At the time of study enrollment, global chronic GVHD severity was mild in 10{\%} (n ∇ 32), moderate in 59{\%} (n ∇ 175), and severe in 31{\%} (n ∇ 91). Skin, lung, or eye scores determined the global severity score in the majority of cases, with the other 5 organs determining 16{\%} of the global severity scores. Conventional risk factors predictive for onset of chronic GVHD and nonrelapse mortality in people with chronic GVHD were not associated with NIH global severity scores. Global severity scores at enrollment were associated with nonrelapsemortality (P < .0001) and survival (P < .0001); 2-year overall survival was 62{\%} (severe), 86{\%} (moderate), and 97{\%} (mild). Patients with mild chronic GVHD have a good prognosis, while patients with severe chronic GVHD have a poor prognosis. This study was registered at www.clinicaltrials.gov as no. NCT00637689.",
author = "Sally Arai and Madan Jagasia and Barry Storer and Xiaoyu Chai and Joseph Pidala and Corey Cutler and Mukta Arora and Weisdorf, {Daniel J.} and Flowers, {Mary E.D.} and Martin, {Paul J.} and Jeanne Palmer and David Jacobsohn and Pavletic, {Steven Z.} and Vogelsang, {Georgia B.} and Lee, {Stephanie J.}",
year = "2011",
month = "10",
day = "13",
doi = "10.1182/blood-2011-03-344390",
language = "English (US)",
volume = "118",
pages = "4242--4249",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria

AU - Arai, Sally

AU - Jagasia, Madan

AU - Storer, Barry

AU - Chai, Xiaoyu

AU - Pidala, Joseph

AU - Cutler, Corey

AU - Arora, Mukta

AU - Weisdorf, Daniel J.

AU - Flowers, Mary E.D.

AU - Martin, Paul J.

AU - Palmer, Jeanne

AU - Jacobsohn, David

AU - Pavletic, Steven Z.

AU - Vogelsang, Georgia B.

AU - Lee, Stephanie J.

PY - 2011/10/13

Y1 - 2011/10/13

N2 - In 2005, the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD proposed a new scoring system for individual organs and an algorithm for calculating global severity (mild, moderate, severe). The Chronic GVHD Consortium was established to test these new criteria. This report includes the first 298 adult patients enrolled at 5 centers of the Consortium. Patients were assessed every 3-6 months using standardized forms recommended by the Consensus Conference. At the time of study enrollment, global chronic GVHD severity was mild in 10% (n ∇ 32), moderate in 59% (n ∇ 175), and severe in 31% (n ∇ 91). Skin, lung, or eye scores determined the global severity score in the majority of cases, with the other 5 organs determining 16% of the global severity scores. Conventional risk factors predictive for onset of chronic GVHD and nonrelapse mortality in people with chronic GVHD were not associated with NIH global severity scores. Global severity scores at enrollment were associated with nonrelapsemortality (P < .0001) and survival (P < .0001); 2-year overall survival was 62% (severe), 86% (moderate), and 97% (mild). Patients with mild chronic GVHD have a good prognosis, while patients with severe chronic GVHD have a poor prognosis. This study was registered at www.clinicaltrials.gov as no. NCT00637689.

AB - In 2005, the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD proposed a new scoring system for individual organs and an algorithm for calculating global severity (mild, moderate, severe). The Chronic GVHD Consortium was established to test these new criteria. This report includes the first 298 adult patients enrolled at 5 centers of the Consortium. Patients were assessed every 3-6 months using standardized forms recommended by the Consensus Conference. At the time of study enrollment, global chronic GVHD severity was mild in 10% (n ∇ 32), moderate in 59% (n ∇ 175), and severe in 31% (n ∇ 91). Skin, lung, or eye scores determined the global severity score in the majority of cases, with the other 5 organs determining 16% of the global severity scores. Conventional risk factors predictive for onset of chronic GVHD and nonrelapse mortality in people with chronic GVHD were not associated with NIH global severity scores. Global severity scores at enrollment were associated with nonrelapsemortality (P < .0001) and survival (P < .0001); 2-year overall survival was 62% (severe), 86% (moderate), and 97% (mild). Patients with mild chronic GVHD have a good prognosis, while patients with severe chronic GVHD have a poor prognosis. This study was registered at www.clinicaltrials.gov as no. NCT00637689.

UR - http://www.scopus.com/inward/record.url?scp=80054090049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054090049&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-03-344390

DO - 10.1182/blood-2011-03-344390

M3 - Article

C2 - 21791424

AN - SCOPUS:80054090049

VL - 118

SP - 4242

EP - 4249

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -